We are live on ! Find out more
ITCI

Intra-Cellular Therapies Inc.
ITCI

Delisted

ITCI was delisted on the 1st of April, 2025.

Back to rankings

4 hedge funds and large institutions have $4.15M invested in Intra-Cellular Therapies Inc. in 2025 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 389 closing their positions.

New
Increased
Maintained
Reduced
Closed

99% less funds holding

Funds holding: 395 → 4 (-391)

100% less capital invested

Capital invested by funds: $13.6B → $4.15M (-$13.6B)

100% less funds holding in top 10

Funds holding in top 10: 52 → 0 (-52)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 389

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Holders
4
Holders Change
-391
Holders Change %
-98.99%
% of All Funds
0.05%
Holding in Top 10
–
Holding in Top 10 Change
-52
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
2
Closed
389
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$1.26B
2
BlackRock
BlackRock
New York
-$1.15B
3
PCM
Pentwater Capital Management
Florida
-$685M
4
HI
HBK Investments
Texas
-$578M
5
Norges Bank
Norges Bank
Norway
-$472M
Name Holding Trade Value Shares
Change 		Change in
Stake
TWD
326
True Wealth Design
Ohio
– -$63.9K -484 Closed
EWA
327
EverSource Wealth Advisors
Alabama
– -$56.5K -428 Closed
MCM
328
Manchester Capital Management
Vermont
– -$55.8K -423 Closed
WA
329
WPG Advisers
Maryland
– -$50.1K -380 Closed
SW
330
SVB Wealth
Massachusetts
– -$47.4K -359 Closed
Daiwa Securities Group
331
Daiwa Securities Group
Japan
– -$47K -355 Closed
SCM
332
Sterling Capital Management
North Carolina
– -$45.5K -345 Closed
AWM
333
Accredited Wealth Management
Kentucky
– -$44.2K -335 Closed
FDCDDQ
334
Federation des caisses Desjardins du Quebec
Quebec, Canada
– -$40.2K -305 Closed
PP
335
PFS Partners
New Jersey
– -$39.6K -300 Closed
AAP
336
Arax Advisory Partners
Colorado
– -$37.5K -284 Closed
AssetMark Inc
337
AssetMark Inc
California
– -$37.1K -281 Closed
Mitsubishi UFJ Asset Management
338
Mitsubishi UFJ Asset Management
Japan
– -$35.4K -268 Closed
MPWT
339
MassMutual Private Wealth & Trust
Connecticut
– -$31.7K -240 Closed
SPIA
340
Steward Partners Investment Advisory
New York
– -$30.7K -233 Closed
SAM
341
Smartleaf Asset Management
Massachusetts
– -$30.1K -228 Closed
PS
342
Principal Securities
Iowa
– -$17.7K -212 Closed
VCM
343
Versant Capital Management
Arizona
– -$26K -197 Closed
MCM
344
MAI Capital Management
Ohio
– -$25.2K -191 Closed
BIG
345
Brooklyn Investment Group
New York
– -$23.9K -181 Closed
AG
346
AmeriFlex Group
Nevada
– -$21.1K -160 Closed
Bessemer Group
347
Bessemer Group
New Jersey
– -$20K -153 Closed
FHA
348
First Horizon Advisors
Tennessee
– -$19.5K -148 Closed
QCG
349
Quadrant Capital Group
Ohio
– -$18.3K -139 Closed
NA
350
NewEdge Advisors
Louisiana
– -$17.7K -134 Closed
12 13
14
15 16

ITCI Hedge Fund Activity: Q2 2025 in Review

4 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q2 2025, worth a combined $4.15M — down 100% from $13.6B a quarter earlier.

Sellers outnumbered buyers: 389 funds closed out of ITCI and 0 opened new positions — a net loss of 389 holders — while 2 trimmed existing stakes and 0 added.

The largest seller was Vanguard Group, exiting entirely with an estimated $1.26B sold.

  • 4 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q2 2025, down from 395 in Q1 2025.
  • Funds reported $4.15M of Intra-Cellular Therapies Inc. stock for Q2 2025, down 100% quarter-over-quarter.
  • 0 funds opened new Intra-Cellular Therapies Inc. positions in Q2 2025 and 389 closed out, a net change of -389 holders.
  • The largest Intra-Cellular Therapies Inc. seller in Q2 2025 was Vanguard Group, an estimated $1.26B sold.

Based on aggregated 13F filings for Q2 2025.